| MSI | Microsatellite instability |
| MMR | Mismatch repair |
| dMMR | MMR deficient |
| pMMR | MMR proficient |
| CRC | Colorectal cancer |
| mCRC | Metastatic colorectal cancer |
| ICI | Immune checkpoint inhibitor |
| MS | Microsatellite |
| MSS | Microsatellite stable |
| IHC | Immunohistochemistry |
| PCR | Polymerase chain reaction |
| NGS | Next generation sequencing |
| ct | Circulating tumor |
| ctDNA | Circulating tumor DNA |
| MLH1 | MutL Homologue 1 |
| MSH2 | MutS Homologue 2 |
| MSH3 | MutS Homologue 3 |
| MSH6 | MutS Homologue 6 |
| PMS2 | Postmeiotic Segregation Increased 2 |
| KRAS | V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog |
| NRAS | Neuroblastoma RAS viral oncogene homolog |
| BRAF | v-Raf murine sarcoma viral oncogene homolog B1 |
| IQR | Interquartile range |
| OS | Overall survival |
| PFS | Progression-free survival |
| CR | Complete response |
| PR | Partial response |
| SD | Stable disease |
| PD | Progressive disease |
| NE | Not evaluable |
| ORR | Overall response rate |
| DCR | Disease control rate |
| VAF | Variant allele frequency |
| bTMB | Blood tumor mutational burden |
| TF | Tumor fraction |
| CI | Confidence interval |
| HR | Hazard ratio |
| SD | Standard deviation |
| CGP | Comprehensive genomic profiling |